COR2ED Medical Education

Medical education: Join Lead Nurse Andreia Fernandes and Clinical Nurse Specialist Jo Pearson as they explain how to help patients navigate the side effects of systemic therapies in endometrial carcinoma. Specialist nurses have a critical role helping women stay on treatment and at home for as long as possible. They discuss their privileged position supporting women with endometrial carcinoma and how they continue to educate and advocate for women in a fast-changing therapeutic environment.

Medical education: Join world-renowned gynaecological oncology experts Dr Domenica “Ketta” Lorusso and Dr Mansoor Mirza as they explore the changing landscape of systemic treatment in endometrial carcinoma. Single-agent immunotherapies (pembrolizumab and dostarlimab), and now immunotherapy and antiangiogenic therapy combinations (pembrolizumab and lenvatinib), are transforming treatment pathways, with OS benefits in the second-line now achievable. They offer tips for managing the toxicity of these novel therapeutic options and set the stage for 2023, a year which promises a paradigm shift in the use of systemic treatments in this once underserved malignancy.

COR2ED Medical Education: This episode, covers the highlights on colorectal cancer from ASCO GI 2023.  Prof. Andrea Sartore-Bianchi (Niguada Cancer Center, Milan, Italy) and Prof. Shubham Pant (MD Anderson Cancer Center, Houston, TX, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice.

The experts start by discussing the SUNLIGHT trial which studied the use of trifluridine/tipiracil plus bevacizumab as third-line treatment in refractory colorectal cancer.  The discussion then moves on to a trial which evaluated the kinetics of post operative circulating cell-free DNA and its impact on minimal residual cell detection in patients with stage I-III colorectal cancer. 

The third abstract the experts discussed was a phase I trial which study botensilimab plus balstilimab in MSS colorectal cancer patients. Finally they discuss the long term results of NRG-GI002, a phase 2 trial which looked at the use of total neoadjuvant therapy in locally advanced rectal cancer. 

COR2ED Medical Education: This episode, covers the highlights on gastroesophageal, gastric and gastroesophageal junction (GEJ) cancer from ASCO GI 2023.  Dr Nataliya Uboha (University of Wisconsin, USA) and Dr Efrat Dotan(Fox Chase Cancer Center, USA) discuss a number of key abstracts from the meeting and their implications for clinical practice.

 The experts start by covering a number of metastatic studies.  First of all, they discuss SPOTLIGHT, a study which investigated the novel agent zolbetuximab as first line treatment in patients with claudin-18.2+/HER2 locally advanced unresectable or metastatic gastroesophageal cancer.  Next they discuss Rationale 305, a study that looked at the activity of tislelizumab in combination with chemotherapy versus chemotherapy alone in patients with PD-L1 positive tumours.  They also discussed the three-year follow up results from CheckMate 649, looking at nivolumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced gastroesophageal cancer.  The discussion then moves on to INTEGRATE IIa, a study comparing regorafenib with placebo in refractory advanced gastroesophageal cancer. 

COR2ED Medical Education: In this podcast, Dr Sarah O’Brien and Dr Homa Ahmadzia discuss gynaecological considerations in women and girls who have an underlying bleeding disorder. The experts discuss the two sides of the coin regarding women with bleeding disorders: women may have uterine bleeding due to their bleeding disorder, however there can also be gynaecological causes for the heavy bleeding. Dr O’Brien and Dr Ahmadzia also review the signs and symptoms of bleeding disorders, as well as gynaecological causes for uterine bleeding including endometriosis, adenomyosis fibroids, and uterine anomalies. They discuss treatment as well as specific situations such as gynaecological surgery, and the importance of collaboration with other specialists.

Dr Sarah O’Brien is a Paediatric Haematologist at Nationwide Children’s Hospital in Columbus, OH, USA and Dr Homa Ahmadzia is a Maternal and Foetal Medicine Physician at George Washington University, DC, USA

COR2ED Medical Education: In this podcast, Prof. Jonathan Trent and Prof. Robin Jones discuss what’s new in the patient management in sarcoma from CTOS 2022. The Connective Tissue Oncology Society is an international group of physicians and scientists with a primary interest in the tumours of connective tissues. With nearly 600 attendees, 10 sessions specific for sarcoma, and over 300 posters, CTOS 2022 took place between November 16 and 19 in Vancouver, BC, Canada. Clinical practice and patient management highlights covered in the podcast include insights from the DEFI study on desmoid tumour, the REECUR study for Ewing sarcoma, and the ENLIVEN study for gastrointestinal stromal tumor (GIST). In addition, early studies with potential clinical impact are discussed.

Prof. Jonathan Trent is Associate Director for Clinical Research, the Director of the Bone and Soft-tissue Sarcoma Group and Medical Director of the Precision Medicine Initiative at the Sylvester Comprehensive Cancer Center in the University of Miami Health System, Miami, FL, USA. Prof. Robin Jones is Head of the Sarcoma Unit at The Royal Marsden NHS Foundation Trust, London, UK.

Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Dr Friederike Schlürmann a Medical Oncologist from University Hospital of Brest and Quimper in France, discuss the clinical implementation of targeted and immunotherapies for advanced renal cell carcinoma (RCC).

In this podcast, the two experts discuss data from key trials CHECKMATE 214 (ipilimumab and nivolumab), KEYNOTE 426 (axitinib and pembrolizumab), CHECKMATE 9ER (cabozantinib and nivolumab), CLEAR (Lenvatinib and pembrolizumab) and COSMIC 313 (cabozantinib plus nivolumab and ipilimumab) and the implications for clinical practice.

They also discuss management of toxicities associated with combination treatments, including dosing strategies to ensure the patient remains on optimal treatment and improved education for patients and clinicians so that they recognise side effects and how to manage them.

COR2ED Medical Education: In this podcast, Prof. Martyn Caplin and Dr Aman Chauhan discuss the role of somatostatin analogues (SSAs) at progression and whether to continue or not. In patients with well-differentiated Grade 1/2 neuroendocrine tumours (NETs) and slowly progressive asymptomatic disease, potential strategies for continuing SSA at progression include increasing the SSA dose frequency from every four to every two weeks, increasing the monthly SSA dose, using SSA as maintenance therapy in stable patients unable to tolerate chemotherapy, and—in patients receiving peptide receptor radionuclide therapy (PRRT)—during and/or post PRRT.

They share their clinical experience and their own clinical practice, based on data from key studies including NETTER-1, CLARINET FORTE, and REMINET, as well as relevant retrospective analyses. Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, London, UK. Dr Aman Chauhan is a Medical Oncologist and Director of NET Theranostics at the University of Kentucky Markey Cancer Center, Kentucky, USA.